A small, randomized trial of patients with COVID-19 demonstrated the ability of colchicine, which indirectly inhibits the NLRP3 inflammasome, to reduce the requirement of oxygen [186], though current NIH guidelines do not recommend colchicine for the treatment of COVID-19 [187]. The gene discussed is NLRP3; the disease is COVID-19.